Medical Treatments: Innovation

(asked on 22nd October 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the (a) criteria used for and (b) long term data collection requirement of the highly specialised technologies process.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 30th October 2018

To date, the National Institute for Health and Care Excellence (NICE) has recommended all eight medicines that it has evaluated through its highly specialised technologies (HST) programme for some or all of the eligible patient population, in most cases subject to managed access agreements that specify clinical criteria and data collection requirements. National Health Service organisations are legally required to fund medicines recommended in NICE’s HST guidance, and patients with the rare diseases concerned are now benefitting from access to the medicines in line with NICE’s recommendations.

Reticulating Splines